ARAT for Reflux Disease After Peroral Endoscopic Myotomy in Patients With Achalasia
Key facts
- Who runs it
- Coordinación de Investigación en Salud, Mexico
- Where
- Mexico1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 44 people, planned
- Started
- 3 Jul 2019
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Treatments tested
- ARAT technique
- Record updated
- 25 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Achalasia type I, II, III
- Treatment with POEM (Peroral Endoscopic Myotomy)
- Abnormal acid exposure (>6%) in the 24h-pHmetry test more than three months after the procedure
- Signed informed consent
Who cannot take part
- Previous antireflux surgery
- Previous Heller's Myotomy
- Patients who do not accept the treatment
- Hiatal hernia greater than 3 centimeters
- Hill's Classification Grade IV
- Pregnancy
- Patients with any contraindication for an endoscopy
- Patients with esophageal or gastric varices
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Achalasia or gastroesophageal reflux
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The peroral endoscopic myotomy for the treatment of achalasia is associated with a higher incidence of gastroesophageal reflux disease compared with Heller's myotomy. Remodeling of the esophagogastric junction with hybrid argon plasma could decrease the passage of gastric or gastroduodenal content into the esophagus.
The group in the trial
- Argon Plasma Coagulation of the gastroesophageal junctionTreatment being tested
Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
Treatment: ARAT technique
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Antireflux Ablation Therapy (ARAT) at Esophagogastric Junction in Patients With Reflux Disease After Peroral Endoscopic Myotomy (POEM) in Achalasia
- Criteria questions
- Built from NCT04065516, who can take part
- Record updated
- 25 April 2025